NCT05670951 is a Phase 3 clinical trial of ELGN-2112 in Intestinal Malabsorption, sponsored by Elgan Pharma Ltd..

Who is sponsoring NCT05670951?

NCT05670951 is sponsored by Elgan Pharma Ltd..

What drugs are being tested in NCT05670951?

Interventions in NCT05670951: ELGN-2112, Placebo.

What condition does NCT05670951 study?

NCT05670951 studies Intestinal Malabsorption.

Is NCT05670951 still recruiting?

NCT05670951 is currently recruiting now. Last updated 22 January 2026.

Last reviewed 2026-01-22 · How we verify

NCT05670951

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Recruiting now Phase 3 Last updated 22 January 2026

What this trial tests

Phase 3 trial testing ELGN-2112 in Intestinal Malabsorption in 360 participants. Currently enrolling.

Timeline

27 February 2025

Primary endpoint
1 November 2027

1 May 2029

Quick facts

Lead sponsor	Elgan Pharma Ltd.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	360
Start date	27 February 2025
Primary completion	1 November 2027
Estimated completion	1 May 2029
Sites	1 location across Israel

Drugs / interventions tested

ELGN-2112 — full drug profile →
Placebo

Conditions studied

Intestinal Malabsorption — all drugs for Intestinal Malabsorption →

Sponsor

Elgan Pharma Ltd. — full company profile →

Who can join

Adults 1 Day to 5 Days, any sex, with Intestinal Malabsorption. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Numbers of days to achieve full enteral feeding
Time frame: 28 days or discharge from hospital

Sponsor's own description

The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Elgan Pharma Ltd. trials

Trials by the same sponsor.

NCT02865122 — Safety and Efficacy Study in Infant With SBS · Phase 2, PHASE3 · terminated
NCT02510560 — Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05670951 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Elgan Pharma Ltd.
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05670951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing